ELZONRIS: payments to doctors
Payments that named ELZONRIS as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.8M
- Providers
- 2,560
- Transactions
- 4,288
- Average per transaction
- $428
The per-transaction average — $428 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,560 providers the average total is $717, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Stemline Therapeutics Inc. | $1,834,244 | 99.9% |
| Nippon Shinyaku Co.,ltd | $2,000 | 0.1% |